Abstract
Background BrainAge models based on neuroimaging data have shown good accuracy for diagnostic classification. However, they have replicability issues due to site and patient variability intrinsic to neuroimaging techniques. We aimed to develop a BrainAge model trained on neuropsychological tests to identify a biomarker to distinguish stable mild cognitive impairment (sMCI) from progressive mild cognitive impairment (pMCI) to Alzheimer’s disease (AD).
Methods Using a linear regressor, a BrainAge model was trained on healthy controls (CN) based on neuropsychological tests. The model was applied to sMCI and pMCI subjects to obtain predicted ages. The BrainAge delta, the predicted age minus the chronological age, was used as a biomarker to distinguish between sMCI and pMCI. We compared the model to one trained on neuroimaging features.
Findings The AUC of the ROC curve for differentiating sMCI from pMCI was 0.91. It greatly outperforms the model trained on neuroimaging features which only obtains an AUC of 0.681. The AUC achieved is at par with the State-of-the-Art BrainAge models that use Deep Learning. The BrainAge delta was correlated with the time to conversion, the time taken for a pMCI subject to convert to AD.
Interpretation We suggest that the BrainAge delta trained only with neuropsychological tests is a good biomarker to distinguish between sMCI and pMCI. This opens up the possibility to study other neurological and psychiatric disorders using this technique but with different neuropsychological tests.
Funding A full list of funding bodies that supported this study can be found in the Acknowledgments section.
Evidence before this study A major application of recent neuroimaging BrainAge models has been demonstrating its value in diagnostic classification. In spite of the good performance, most models based on neuroimaging data have limitations in real data as the distribution between sites can be different from training cohorts. They can also suffer from lack of specificity to a disease, for those based on BrainAge deltas trained on healthy controls or insufficient training data, for those trained to directly identify a specific disease. We develop a BrainAge model trained on neuropsychological tests used in Alzheimer’s disease research to identify a biomarker to distinguish sMCI from pMCI subjects. We propose a model that is trained on healthy controls for which there is more data to then reliably distinguish sMCI from pMCI subjects.
Added value of this study This is the first study to use a BrainAge model based on neuropsychological test features to study Alzheimer’s disease. We suggest the NeuropsychBrainAge delta, which measure the difference between the model predicted age of the subject trained on healthy controls and the chronological age of the subject, as a biomarker of Alzheimer’s Disease. The NeuropsychBrainAge delta could differentiate between sMCI and pMCI. Moreover, we also show that the proposed biomarker is correlated with the time to conversion, the time taken for a pMCI subject to convert to Alzheimer’s Disease.
Implications of all the available evidence Our approach could be used for the identification of patients with mild cognitive impairment at risk of developing Alzheimer’s disease. The NeuropsychBrainAge delta can also be used as a quantitative marker to measure disease severity due to its correlation with time to conversion. This study shows that using healthy controls for which there is more data but using features specific to a disease such as neuropsychological test can lead to reliable BrainAge models to identify specific neurological and psychiatric disorders.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The project that gave rise to these results received the support of a fellowship from la Caixa Foundation ID 100010434 The fellowship code is LCFBQDI2111860030 JMC is funded by Ikerbasque The Basque Foundation for Science and by the Department of Economic Development and Infrastructure of the Basque Country Elkartek Program Grant KK202100009 Data collection and sharing for this project was funded by the Alzheimers Disease Neuroimaging Initiative ADNI National Insti tutes of Health Grant U01 AG024904 and DOD ADNI Department of Defense award number W81XWH1220012 ADNI is funded by the National Institute on Aging the National Institute of Biomedical Imaging and Bioengineering and through generous contributions from the following AbbVie Alzheimers Association Alzheimers Drug Discovery Foundation Araclon Biotech BioClinica Inc Biogen BristolMyers Squibb Company CereSpir IncEisai Inc Elan Pharmaceuticals Inc Eli Lilly and Company EuroImmun F HoffmannLa Roche Ltd and its affiliated company Genentech Inc Fujirebio GE Healthcare IXICO Ltd Janssen Alzheimer Immuno therapy Research Development LLC Johnson Johnson Pharma ceutical Research Development LLC Lumosity Lundbeck Merck Co Inc Meso Scale Diagnostics LLC NeuroRx Research Neurotrack Technologies Novartis Pharmaceuticals Corporation Pfizer Inc Piramal Imaging Servier Takeda Pharmaceutical Com pany and Transition Therapeutics The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada Private sector contributions are facilitated by the Foundation for the National Institutes of Health wwwfnihorg The grantee organization is the Northern California Institute for Research and Education and the study is coordinated by the Alzheimers Disease Cooperative Study at the University of California San Diego ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study used ONLY openly available human data that were originally located at: Alzeihmer's Disease Neuroimaging Initiative (ADNI)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵1 Data used in preparation of this article were obtained from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in analysis or writing of this report. A complete listing of ADNI investigators can be found at: http://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf.
Data Availability
All data produced in the present study are available upon reasonable request to ADNI.
